Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients

Leukemia. 2014 Apr;28(4):967-70. doi: 10.1038/leu.2014.31. Epub 2014 Jan 20.

Authors

G Visani¹, F Ferrara², F Di Raimondo³, F Loscocco¹, G Sparaventi¹, S Paolini⁴, F Fuligni⁴, A Gazzola⁴, M Rossi⁴, M A Laginestra⁴, M R Caraci³, C Riccardi², M Rocchi⁵, A Visani⁴, S A Pileri⁴, P P Piccaluga⁴, A Isidori¹

Affiliations

¹ Hematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy.
² Hematology, Cardarelli Hospital, Napoli, Italy.
³ Hematology, Catania University, Catania, Italy.
⁴ Hematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.
⁵ Institute of Biomathematics, Urbino University, Urbino, Italy.

PMID: 24441289
DOI: 10.1038/leu.2014.31

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / administration & dosage
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Lenalidomide
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Prospective Studies
Remission Induction
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives

Substances

Cytarabine
Thalidomide
Lenalidomide